News & Updates
– Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to…
Read More
Christopher Kata and the TrialStat team are attend this years “SoCalBio 25th Annual Conference” meeting on October 25th through the 26th in Long Beach, California. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting! We’re looking forward to meeting with you and providing live, personalized demonstrations of…
Read More
First Phase III results in breast cancer for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan Plans for global regulatory submissions underway Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival…
Read More
Excerpt from the Press Release: OAKLAND, Calif., Sept. 21, 2023 /PRNewswire/ — Via Nova Therapeutics, Inc., a biotechnology company focused on discovering and developing therapeutics to treat viral infections with significant unmet medical need, today announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its…
Read More
– Findings show viral proteins outside of Spike across Alpha, Beta, Gamma, Delta and Omicron SARS-CoV-2 variants are responsible for innate immune suppression and escape from human immune system barriers – Elucidation of common evolutionary thread provides key biologic target against future COVID-19 variants and other pandemics Excerpt from the Press Release: SAN FRANCISCO and…
Read More
Excerpt from the Press Release: MALVERN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial…
Read More
Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL Excerpt from the Press Release: PALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that the first patient has been…
Read More
Christopher Kata and the TrialStat team are attend this years “Octane Medical Innovations Forum” meeting on October 25th through the 26th in Irvine, California. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting! We’re looking forward to meeting with you and providing live, personalized demonstrations of our…
Read More
Logica, an offering from Charles River and Valo Health, will be used to discover first-in-class therapeutics against high value targets in the Related Sciences portfolio Excerpt from the Press Release: WILMINGTON, Mass. & DENVER–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program…
Read More
Excerpt from the Press Release: Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q) Devon, PA, September 14, 2023 – Zynerba Pharmaceuticals, Inc.…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?